Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitomycin-C in breast cancer.

G N Hortobagyi

    Seminars in Oncology
    |December 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Mitomycin-C, an antitumor antibiotic, shows effectiveness in breast cancer treatment. Different administration schedules and drug combinations impact its efficacy and toxicity profile.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

    ESMO open·2025
    Same author

    Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329].

    Annals of oncology : official journal of the European Society for Medical Oncology·2022
    Same author

    Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same journal

    A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

    Seminars in oncology·2026
    Same journal

    Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

    Seminars in oncology·2026
    Same journal

    PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

    Seminars in oncology·2026
    Same journal

    Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

    Seminars in oncology·2026
    Same journal

    Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

    Seminars in oncology·2026
    Same journal

    Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

    Seminars in oncology·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Mitomycin-C, an antitumor antibiotic, functions as a bifunctional alkylating agent.
    • Early daily administration schedules caused severe myelosuppression, limiting its therapeutic evaluation.

    Purpose of the Study:

    • To review the evolving administration schedules and combination therapies of Mitomycin-C.
    • To assess the efficacy and toxicity of Mitomycin-C in breast cancer treatment.

    Main Methods:

    • Review of clinical trials and investigator reports on Mitomycin-C administration.
    • Analysis of response rates and toxicities associated with various Mitomycin-C regimens.

    Main Results:

    • Intermittent high-dose schedules (20 mg/m2 every 6-8 weeks) yielded a 35% overall response rate.

    Related Experiment Videos

  • Combinations with vinca alkaloids showed 30-40% response rates in pre-treated patients.
  • Combinations with doxorubicin achieved ~50% response rates in doxorubicin-naïve patients.

    • Conclusions:

    • Mitomycin-C demonstrates efficacy in breast cancer, particularly in combination therapies.
    • Careful incorporation into therapeutic strategies is recommended, considering its toxicity profile.